Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes
ConclusionLu-TLX591 was safely administered at acceptable toxicity and its efficacy reflects previous clinical trials. Larger studies are required and are underway (NCT04786847; NCT05146973; NCT04876651) to determine Lu-TLX591 effectiveness amongst different prostate cancer populations and compare its efficacy against peptide-based radiopharmaceutical agents.
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research
More News: Anemia | Anorexia | Australia Health | Cancer | Cancer & Oncology | Clinical Trials | Eating Disorders & Weight Management | Molecular Biology | PET Scan | Prostate Cancer | Radiology | Study | Thrombocytopenia | Toxicology